Have you or your loved ones been diagnosed with carcinoma, non-small-cell lung?

You may be eligible to participate in a carcinoma, non-small-cell lung clinical trial.

Have you or your loved ones been diagnosed with carcinoma, non-small-cell lung? You may be eligible to participate in a carcinoma, non-small-cell lung clinical trial.

What is a clinical trial? Is participating in a clinical trial right for you? Learn more

Carcinoma, Non-Small-Cell Lung Clinical Trial in Philadelphia PA
NCT02710396 | Phase 2 | Interventional
Naiyer Rizvi
Sponsored by
Naiyer Rizvi

Have you or your loved ones been diagnosed with carcinoma, non-small-cell lung?

You may be eligible to participate in a carcinoma, non-small-cell lung clinical trial.

Have you or your loved ones been diagnosed with carcinoma, non-small-cell lung? You may be eligible to participate in a carcinoma, non-small-cell lung clinical trial.

Active not recruiting

Male & Female

18 Years +

This study has recruited 18 Participants

The primary objective is to determine if mutation load underlies sensitivity to pembrolizumab alone and in combination with chemotherapy. This will be a 3-arm, multi-center, open-label, non-randomized biomarker trial in patients with advanced, treatment-naive NSCLC. Patients will receive 1 of 3 possible cohorts as per investigator's discretion. Patients with non-squamous histology may receive any of the 3 cohorts; patients with squamous histology may receive either cohorts 1 and 2.